- Clinical-stage biopharmaceutical firm Salarius Pharmaceuticals ( NASDAQ: SLRX ) and VolitionRx ( NYSE: VNRX ), a developer of blood tests, have signed a research and development agreement, the companies said on Tuesday.
- Salarius ( SLRX ) stock jumped 15.8% to $0.21 in premarket trading, while shares of VNRX had gained 6.5% to $2.13.
- As per the agreement, VNRX's Nu.Q technology will be used to glean biomarker information and advance rapid epigenetic profiling of Salarius' drug candidate seclidemstat.
- Financial terms of the agreement were not disclosed.
- Seclidemstat is currently being evaluated in phase 1/2 studies for solid and hematologic cancers.
- VNRX's Nu.Q was developed as an easy-to-use blood test to diagnose and monitor a range of life-altering diseases including cancer.
For further details see:
Salarius Pharmaceuticals and VolitionRx enter into R&D collaboration agreement